RARE Earnings

RARE reported its FY2025Q3 earnings on 2025-11-04, showcasing a revenue of 159.93M against an estimate of 166.79M, resulting in a -4.11% surprise. The EPS was -1.81, surpassing the expected -1.23 by -47.15%. The stock experienced a -1.82% price change on the earnings day and a -1.6% change over the next five days, reflecting market reactions to the results.

Following RARE's FY2025Q3 earnings announcement on 2025-11-04, the stock price moved by -1.82% on the day of the release. Over the subsequent five days, it saw a -1.6% change. Historically, RARE's stock price tends to shift by an average of -0.79% in the 10 days leading up to earnings and 1.63% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate RARE's annual revenue to reach 172.08M, while the EPS is projected at -1.42. These estimates reflect recent revisions, with revenue estimates revised downward by -0.13% and EPS estimates revised upward by 0.05% over the past three months, indicating analyst expectation in the company's performance.

The correlation between RARE's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised downward by -0.13%, while EPS estimates moved revised upward by 0.05%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, RARE's stock price typically moves by -0.79% in the 10 days before its earnings and 1.63% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -1.42 and revenue of 172.08M.

The earnings call summary and Q&A session reveal several positive indicators: strong revenue guidance for 2025, a clear path to profitability by 2027, and a solid financial position with significant nondilutive capital. Additionally, the company is preparing for potential product launches, and management demonstrates confidence in meeting regulatory criteria for ongoing studies. Although some uncertainties remain, such as the timeline for the IRL resubmission, the overall sentiment is positive, suggesting a likely stock price increase.